Structure-activity studies on the spiroketal moiety of a simplified analogue of debromoaplysiatoxin with antiproliferative activity

Journal of Medicinal Chemistry

Volumn 55, Issue 11, 2012, Pages 5614-5626

  Kikumori, Masayuki ^a   Yanagita, Ryo C ^a,b   Tokuda, Harukuni ^c   Suzuki, Nobutaka ^c   Nagai, Hiroshi ^d   Suenaga, Kiyotake ^e   Irie, Kazuhiro ^a  

^a KYOTO UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

^d TOKYO UNIVERSITY OF MARINE SCIENCE AND TECHNOLOGY   (Japan)

^e KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLAPLOG 1; APLOG 1; DEBROMOAPLYSIATOXIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOGENS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISOENZYMES; LYNGBYA TOXINS; MALE; MICE; MICE, INBRED ICR; PROTEIN BINDING; PROTEIN KINASE C; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84862275351     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300566h     Document Type: Article

References (76)

1. Berenblum, I. The Mechanism of Carcinogenesis. A Study of the Significance of Cocarcinogenic Action and Related Phenomena Cancer Res. 1941, 1, 807-814
2. Castagna, M.; Takai, Y.; Kaibuchi, K.; Sano, K.; Kikkawa, U.; Nishizuka, Y. Direct Activation of Calcium-Activated, Phospholipid-Dependent Protein Kinase by Tumor-Promoting Phorbol Esters J. Biol. Chem. 1982, 257, 7847-7851
3. Nishizuka, Y. Protein Kinase C and Lipid Signaling for Sustained Cellular Responses FASEB J. 1995, 9, 484-496
4. Newton, A. C. Protein Kinase C: Structural and Spatial Regulation by Phosphorylation, Cofactors, and Macromolecular Interactions Chem. Rev. 2001, 101, 2353-2364
5. Fujiki, H.; Sugimura, T. New Classes of Tumor Promoters: Teleocidin, Aplysiatoxin, and Palytoxin Adv. Cancer Res. 1987, 49, 223-264
6. Fährmann, M. Targeting Protein Kinase C (PKC) in Physiology and Cancer of the Gastric Cell System Curr. Med. Chem 2008, 15, 1175-1191
7. Griner, E. M.; Kazanietz, M. G. Protein Kinase C and Other Diacylglycerol Effectors in Cancer Nat. Rev. Cancer 2007, 7, 281-294
8. Mackay, H. J.; Twelves, C. J. Targeting the Protein Kinase C Family: Are We There Yet? Nat. Rev. Cancer 2007, 7, 554-562
9. Teicher, B. A. Protein Kinase C as a Therapeutic Target Clin. Cancer Res. 2006, 12, 5336-5345
10. Ishii, H.; Jirousek, M. R.; Koya, D.; Takagi, C.; Xia, P.; Clermont, A.; Burselll, S. E.; Kern, T. S.; Ballas, L. M.; Heath, W. F.; Stramm, L. E.; Feener, E. P.; King, G. L. Amelioration of Vascular Dysfunctions in Diabetic Rats by an Oral PKCβ Inhibitor Science 1996, 272, 728-731
11. Savage, M. J.; Trusko, S. P.; Howland, D. S.; Pinsker, L. R.; Mistretta, S.; Reaume, A. G.; Greenberg, B. D.; Siman, R.; Scott, R. W. Turnover of Amyloid β-Protein in Mouse Brain and Acute Reduction of Its Level by Phorbol Ester J. Neurosci. 1998, 18, 1743-1752
12. Mach, U. R.; Lewin, N. E.; Blumberg, P. M.; Kozikowski, A. P. Synthesis and Pharmacological Evaluation of 8- and 9-Substituted Benzolactam-V8 Derivatives as Potent Ligands for Protein Kinase C, a Therapeutic Target for Alzheimer's Disease ChemMedChem 2006, 1, 307-314
13. Choi, D.-S.; Wang, D.; Yu, G.-Q.; Zhu, G.; Kharazia, V. N.; Paredes, J. P.; Chang, W. S.; Deitchman, J. K.; Mucke, L.; Messing, R. O. PKCε Increases Endothelin Converting Enzyme Activity and Reduces Amyloid Plaque Pathology in Transgenic Mice Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 8215-8220
14. Roebuck, K. A.; Gu, D. S.; Kagnoff, M. F. Activating Protein-1 Cooperates with Phorbol Ester Activation Signals To Increase HIV-1 Expression AIDS 1996, 10, 819-826
15. Pettit, G. R.; Herald, C. L.; Doubek, D. L.; Herald, D. L.; Arnold, E.; Clardy, J. Isolation and Structure of Bryostatin 1 J. Am. Chem. Soc. 1982, 104, 6846-6848
16. Hale, K. J.; Hummersone, M. G.; Manaviazar, S.; Frigerio, M. The Chemistry and Biology of the Bryostatin Antitumour Macrolides Nat. Prod. Rep. 2002, 19, 413-453
17. Hennings, H.; Blumberg, P. M.; Pettit, G. R.; Herald, C. L.; Shores, R.; Yuspa, S. H. Bryostatin 1, an Activator of Protein Kinase C, Inhibits Tumor Promotion by Phorbol Esters in SENCAR Mouse Skin Carcinogenesis 1987, 8, 1343-1346
18. 3H]bryostatin 1 and Analogs to Calcium-Dependent and Calcium-Independent Protein Kinase C Isozymes Mol. Pharmacol. 1994, 46, 374-379
19. Propper, D. J.; Macaulay, V.; O'Byrne, K. J.; Braybrooke, J. P.; Wilner, S. M.; Ganesan, T. S.; Talbot, D. C.; Harris, A. L. A Phase II Study of Bryostatin 1 in Metastatic Malignant Melanoma Br. J. Cancer 1998, 78, 1337-1341
20. Zonder, J. A.; Shields, A. F.; Zalupski, M.; Chaplen, R.; Heilbrun, L. K.; Arlauskas, P.; Philip, P. A. A Phase II Trial of Bryostatin 1 in the Treatment of Metastatic Colorectal Cancer Clin. Cancer Res. 2001, 7, 38-42
21. Ajani, J. A.; Jiang, Y.; Faust, J.; Chang, B. B.; Ho, L.; Yao, J. C.; Rousey, S.; Dakhil, S.; Cherny, R. C.; Craig, C.; Bleyer, A. A Multi-Center Phase II Study of Sequential Paclitaxel and Bryostatin-1 (NSC 339555) in Patients with Untreated, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Invest. New Drugs 2006, 24, 353-357
22. Koutcher, J. A.; Motwani, M.; Zakian, K. L.; Li, X. K.; Matei, C.; Dyke, J. P.; Ballon, D.; Yoo, H. H.; Schwartz, G. K. The in Vivo Effect of Bryostatin-1 on Paclitaxel-Induced Tumor Growth, Mitotic Entry, and Blood Flow Clin. Cancer Res. 2000, 6, 1498-1507
23. Ku, G. Y.; Ilson, D. H.; Schwartz, L. H.; Capanu, M.; O'Reilly, E.; Shah, M. A.; Kelsen, D. P.; Schwartz, G. K. Phase II Trial of Sequential Paclitaxel and 1 h Infusion of Bryostatin-1 in Patients with Advanced Esophageal Cancer Cancer Chemother. Pharmacol. 2008, 62, 875-880
24. Barr, P. M.; Lazarus, H. M.; Cooper, B. W.; Schluchter, M. D.; Panneerselvam, A.; Jacobberger, J. W.; Hsu, J. W.; Janakiraman, N.; Simic, A.; Dowlati, A.; Remick, S. C. Phase II Study of Bryostatin 1 and Vincristine for Aggressive Non-Hodgkin Lymphoma Relapsing after an Autologous Stem Cell Transplant Am. J. Hematol. 2009, 84, 484-487
25. Schaufelberger, D. E.; Koleck, M. P.; Beutler, J. A.; Vatakis, A. M.; Alvarado, A. B.; Andrew, P.; Marzo, L. V.; Muschik, G. M.; Roach, J.; Ross, J. T.; Lebherz, W. B.; Reeves, M. P.; Eberwein, R. M.; Rodgers, L. L.; Testerman, R. P.; Snader, K. M.; Forenza, S. The Large-Scale Isolation of Bryostatin 1 from Bugula neritina following Current Good Manufacturing Practices J. Nat. Prod. 1991, 54, 1265-1270
26. Kageyama, M.; Tamura, T.; Nantz, M. H.; Roberts, J. C.; Somfai, P.; Whritenour, D. C.; Masamune, S. Synthesis of Bryostatin 7 J. Am. Chem. Soc. 1990, 112, 7407-7408
27. Evans, D. A.; Carter, P. H.; Carreira, E. M.; Charette, A. B.; Prunet, J. A.; Lautens, M. Total Synthesis of Bryostatin 2 J. Am. Chem. Soc. 1999, 121, 7540-7552
28. Ohmori, K.; Ogawa, Y.; Obitsu, T.; Ishikawa, Y.; Nishiyama, S.; Yamamura, S. Total Synthesis of Bryostatin 3 Angew. Chem., Int. Ed. 2000, 39, 2290-2294
29. Halford, B. The Bryostatin's Tale Chem. Eng. News 2011, October 24) 11-19
30. Wender, P. A.; Baryza, J. L.; Bennett, C. E.; Bi, F. C.; Brenner, S. E.; Clarke, M. O.; Horan, J. C.; Kan, C.; Lacôte, E.; Lippa, B.; Nell, P. G.; Turner, T. M. The Practical Synthesis of a Novel and Highly Potent Analogue of Bryostatin J. Am. Chem. Soc. 2002, 124, 13648-13649
31. Wender, P. A.; Baryza, J. L.; Brenner, S. E.; DeChristopher, B. A.; Loy, B. A.; Schrier, A. J.; Verma, V. A. Design, Synthesis, and Evaluation of Potent Bryostatin Analogs that Modulate PKC Translocation Selectivity Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6721-6726
32. Keck, G. E.; Kraft, M. B.; Truong, A. P.; Li, W.; Sanchez, C. C.; Kedei, N.; Lewin, N. E.; Blumberg, P. M. Convergent Assembly of Highly Potent Analogues of Bryostatin 1 via Pyran Annulation: Bryostatin Look-Alikes That Mimic Phorbol Ester Function J. Am. Chem. Soc. 2008, 130, 6660-6661
33. Keck, G. E.; Li, W.; Kraft, M. B.; Kedei, N.; Lewin, N. E.; Blumberg, P. M. The Bryostatin 1 A-Ring Acetate Is Not the Critical Determinant for Antagonism of Phorbol Ester-Induced Biological Responses Org. Lett. 2009, 11, 2277-2280
34. Trost, B. M.; Dong, G. Total Synthesis of Bryostatin 16 Using Atom-Economical and Chemoselective Approaches Nature 2008, 456, 485-488
35. Trost, B. M.; Dong, G. Total Synthesis of Bryostatin 16 Using a Pd-Catalyzed Diyne Coupling as Macrocyclization Method and Synthesis of C20- epi -Bryostatin 7 as a Potent Anticancer Agent J. Am. Chem. Soc. 2010, 132, 16403-16416
36. Wender, P. A.; Schrier, A. J. Total Synthesis of Bryostatin 9 J. Am. Chem. Soc. 2011, 133, 9228-9231
37. Keck, G. E.; Poudel, Y. B.; Cummins, T. J.; Rudra, A.; Covel, J. A. Total Synthesis of Bryostatin 1 J. Am. Chem. Soc. 2011, 133, 744-747
38. Manaviazar, S.; Frigerio, M.; Bhatia, G. S.; Hummersone, M. G.; Aliev, A. E.; Hale, K. J. Enantioselective Formal Total Synthesis of the Antitumor Macrolide Bryostatin 7 Org. Lett. 2006, 8, 4477-4480
39. Lu, Y.; Woo, S. K.; Krische, M. J. Total Synthesis of Bryostatin 7 via C-C Bond-Forming Hydrogenation J. Am. Chem. Soc. 2011, 133, 13876-13879
40. Nakagawa, Y.; Yanagita, R. C.; Hamada, N.; Murakami, A.; Takahashi, H.; Saito, N.; Nagai, H.; Irie, K. A Simple Analogue of Tumor-Promoting Aplysiatoxin Is an Antineoplastic Agent Rather Than a Tumor Promoter: Development of a Synthetically Accessible Protein Kinase C Activator with Bryostatin-like Activity J. Am. Chem. Soc. 2009, 131, 7573-7579
41. Yanagita, R. C.; Kamachi, H.; Tanaka, K.; Murakami, A.; Nakagawa, Y.; Tokuda, H.; Nagai, H.; Irie, K. Role of the Phenolic Hydroxyl Group in the Biological Activities of Simplified Analogue of Aplysiatoxin with Antiproliferative Activity Bioorg. Med. Chem. Lett. 2010, 20, 6064-6066
42. Irie, K.; Yanagita, R. C.; Nakagawa, Y. Challenges to the Development of Bryostatin-Type Anticancer Drugs Based on the Activation Mechanism of Protein Kinase Cδ Med. Res. Rev 2012, 32, 518-535
43. Nakagawa, Y.; Kikumori, M.; Yanagita, R. C.; Murakami, A.; Tokuda, H.; Nagai, H.; Irie, K. Synthesis and Biological Evaluation of the 12,12-Dimethyl Derivative of Aplog-1, an Anti-Proliferative Analog of Tumor-Promoting Aplysiatoxin Biosci., Biotechnol., Biochem. 2011, 75, 1167-1173
44. Irie, K.; Kikumori, M.; Kamachi, H.; Tanaka, K.; Murakami, A.; Yanagita, R. C.; Tokuda, H.; Suzuki, N.; Nagai, H.; Suenaga, K.; Nakagawa, Y. Synthesis and Structure-Activity Studies of Simplified Analogues of Aplysiatoxin with Antiproliferative Activity like Bryostatin-1 Pure Appl. Chem. 2012, 84, 1341-1351
45. Kato, Y.; Scheuer, P. J. Aplysiatoxin and Debromoaplysiatoxin, Constituents of the Marine Mollusk Stylocheilus longicauda (Quoy and Gaimard, 1824) J. Am. Chem. Soc. 1974, 96, 2245-2246
46. Park, P. U.; Broka, C. A.; Johson, B. F.; Kishi, Y. Total Synthesis of Debromoaplysiatoxin and Aplysiatoxin J. Am. Chem. Soc. 1987, 109, 6205-6207
47. Ide, M.; Nakata, M. Room-Temperature Metallation of 2-Substituted 1,3-Dithiane Derivatives and Subsequent Coupling with 2,3-Disubstituted Oxiranes Bull. Chem. Soc. Jpn. 1999, 72, 2491-2499
48. Keck, G. E; Krishnamurthy, D. Catalytic Asymmetric Allylation Reactions: (S)-1-(Phenylmethoxy)-4-penten-2-ol Org. Synth. 1998, 75, 12-18
49. Hanawa, H.; Uraguchi, D.; Konishi, S.; Hashimoto, T.; Maruoka, K. Catalytic Asymmetric Allylation of Aldehydes and Related Reactions with Bis(((S)-binaphthoxy)(isopropoxy)titanium) Oxide as a μ-Oxo-Type Chiral Lewis Acid Chem.-Eur. J. 2003, 9, 4405-4413
50. Inanaga, J.; Hirata, K.; Saeki, H.; Katsuki, T.; Yamaguchi, M. A Rapid Esterification by Means of Mixed Anhydride and Its Application to Large-Ring Lactonization Bull. Chem. Soc. Jpn. 1979, 52, 1989-1993
51. Brown, H. C.; Jadhav, P. K. Asymmetric Carbon-Carbon Bond Formation via B-Allyldiisopinocampheylborane. Simple Synthesis of Secondary Homoallylic Alcohols with Excellent Enantiomeric Purities J. Am. Chem. Soc. 1983, 105, 2092-2093
52. Duan, J. J.-W.; Smith, A. B., III. Iodine Monobromide (IBr) at Low Temperature: Enhanced Diastereoselectivity in Electrophilic Cyclizations of Homoallylic Carbonates J. Org. Chem. 1993, 58, 3703-3711
53. Yamori, T.; Matsunaga, A.; Sato, S.; Yamazaki, K.; Komi, A.; Ishizu, K.; Mita, I.; Edatsugi, H.; Matsuba, Y.; Takezawa, K.; Nakanishi, O.; Kohno, H.; Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. Potent Antitumor Activity of MS-247, a Novel DNA Minor Groove Binder, Evaluated by an in Vitro and in Vivo Human Cancer Cell Line Panel Cancer Res. 1999, 59, 4042-4049
54. Partition Coefficient (n -Octanol/Water), High Performance Liquid Chromatography (HPLC) Method. In OECD Guidelines for Testing of Chemicals. Section 1: Physical-Chemical Properties; OECD Publishing: Paris, 1989; Test No. 117.
55. Ito, Y.; Yanase, S.; Fujita, J.; Harayama, T.; Takashima, M.; Imanaka, H. A Short-Term in Vitro Assay for Promoter Substances Using Human Lymphoblastoid Cells Latently Infected with Epstein-Barr Virus Cancer Lett. 1981, 13, 29-37
56. zur Hausen, H.; Bornkamm, G. W.; Schmidt, R.; Hecker, E. Tumor Initiators and Promoters in the Induction of Epstein-Barr Virus Proc. Natl. Acad. Sci. U.S.A. 1979, 76, 782-785
57. Suganuma, M.; Fujiki, H.; Tahira, T.; Cheuk, C.; Moore, R. E.; Sugimura, T. Estimation of Tumor Promoting Activity and Structure-Function Relationships of Aplysiatoxins Carcinogenesis 1984, 5, 315-318
58. Nakamura, H.; Kishi, Y.; Pajares, M. A.; Rando, R. R. Structural Basis of Protein Kinase C Activation by Tumor Promoters Proc. Natl. Acad. Sci. U.S.A. 1989, 86, 9672-9676
59. Shindo, M.; Irie, K.; Nakahara, A.; Ohigashi, H.; Konishi, H.; Kikkawa, U.; Fukuda, H.; Wender, P. A. Toward the Identification of Selective Modulators of Protein Kinase C (PKC) Isozymes: Establishment of a Binding Assay for PKC Isozymes Using Synthetic C1 Peptide Receptors and Identification of the Critical Residues Involved in the Phorbol Ester Binding Bioorg. Med. Chem. 2001, 9, 2073-2081
60. Quest, A. F. G.; Bell, R. M. The Regulatory Region of Protein Kinase Cγ. Studies of Phorbol Ester Binding to Individual and Combined Functional Segments Expressed as Glutathione S -Transferase Fusion Proteins Indicate a Complex Mechanism of Regulation by Phospholipids, Phorbol Esters, and Divalent Cations J. Biol. Chem. 1994, 269, 20000-20012
61. 2+ and Diacylglycerol Biochem. J. 2003, 370, 901-912
62. Szállási, Z.; Bögi, K.; Gohari, S.; Biro, T.; ács, P.; Blumberg, P. M. Non-Equivalent Roles for the First and Second Zinc Fingers of Protein Kinase Cδ: Effect of Their Mutation on Phorbol Ester-Induced Translocation in NIH 3T3 Cells J. Biol. Chem. 1996, 271, 18299-18301
63. Masuda, A.; Irie, K.; Nakagawa, Y.; Ohigashi, H. Binding Selectivity of Conformationally Restricted Analogues of (-)-Indolactam-V to the C1 Domains of Protein Kinase C Isozymes Biosci., Biotechnol., Biochem 2002, 66, 1615-1617
64. 3H]Phorbol 12,13-Dibutyrate Binding Cancer Res. 1985, 45, 19-24
65. Irie, K.; Nakagawa, Y.; Ohigashi, H. Indolactam and Benzolactam Compounds as New Medicinal Leads with Binding Selectivity for C1 Domains of Protein Kinase C Isozymes Curr. Pharm. Des 2004, 10, 1371-1385
66. Haughian, J. M.; Reno, E. M.; Thorne, A. M.; Bradford, A. P. Protein Kinase Cα-Dependent Signaling Mediates Endometrial Cancer Cell Growth and Tumorigenesis Int. J. Cancer 2009, 125, 2556-2564
67. Mandil, R.; Ashkenazi, E.; Blass, M.; Kronfeld, I.; Kazimirsky, G.; Rosenthal, G.; Umansky, F.; Lorenzo, P. S.; Blumberg, P. M.; Brodie, C. Protein Kinase Cα and Protein Kinase Cδ Play Opposite Roles in the Proliferation and Apoptosis of Glioma Cells Cancer Res. 2001, 61, 4612-4619
68. Lu, Z.; Hornia, A.; Jiang, Y.-W.; Zang, Q.; Ohno, S.; Foster, D. A. Tumor Promotion by Depleting Cells of Protein Kinase Cδ Mol. Cell. Biol. 1997, 17, 3418-3428
69. Reddig, P. J.; Dreckschmidt, N. E.; Ahrens, H.; Simsiman, R.; Tseng, C.-P.; Zou, J.; Oberley, T. D.; Verma, A. K. Transgenic Mice Overexpressing Protein Kinase Cδ in the Epidermis Are Resistant to Skin Tumor Promotion by 12- O -Tetradecanoylphorbol-13-acetate Cancer Res. 1999, 59, 5710-5718
70. Jeffrey, A. M.; Liskamp, R. M. J. Computer-Assisted Molecular Modeling of Tumor Promoters: Rationale for the Activity of Phorbol Esters, Teleocidin B, and Aplysiatoxin Proc. Natl. Acad. Sci. U.S.A. 1986, 83, 241-245
71. Zhang, G.; Kazanietz, M. G.; Blumberg, P. M.; Hurley, J. H. Crystal Structure of the Cys2 Activator-Binding Domain of Protein Kinase Cδ in Complex with Phorbol Ester Cell 1995, 81, 917-924
72. Bertolini, T. M.; Giorgione, J.; Harvey, D. F.; Newton, A. C. Protein Kinase C Translocation by Modified Phorbol Esters with Functionalized Lipophilic Regions J. Org. Chem. 2003, 68, 5028-5036
73. Irie, K.; Oie, K.; Nakahara, A.; Yanai, Y.; Ohigashi, H.; Wender, P. A.; Fukuda, H.; Konishi, H.; Kikkawa, U. Molecular Basis for Protein Kinase C Isozyme-Selective Binding: The Synthesis, Folding, and Phorbol Ester Binding of the Cysteine-Rich Domains of All Protein Kinase C Isozymes J. Am. Chem. Soc. 1998, 120, 9159-9167
74. Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines J. Natl. Cancer Inst. 1991, 83, 757-766
75. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening J. Natl. Cancer Inst. 1990, 82, 1107-1112
76. Sakuma, M. Probit Analysis of Preference Data Appl. Entomol. Zool. 1998, 33, 339-347